Sarcopenia and frailty in lymphoma patients getting CAR-T therapy
Part of Brain & nervous system clinical trials.
This trial looks at how muscle loss (sarcopenia) and overall health affect outcomes in people with B-cell lymphoma who are receiving CAR-T cell therapy. It may help doctors better support patients before and after treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have B-cell non-Hodgkin lymphoma and your doctor has recommended CAR-T cell therapy.
- You have had a PET/CT scan or full-dose CT scan (without contrast dye) before starting CAR-T therapy.
- You are willing to sign a consent form agreeing to take part in the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how muscle loss (sarcopenia) might affect side effects from cancer treatments. If you are starting a new cancer treatment, a CT scan before treatment can help doctors predict your risk of side effects.
This study evaluates how to better assess and manage frailty (age-related weakness and vulnerability) in older cancer patients aged 70 and up who are starting chemotherapy or other cancer treatments. The goal is to help doctors tailor treatment plans to each patient's individual strength and health status.
This study looks at muscle loss in people with liver cancer who are receiving targeted therapy (TKIs). It aims to understand how muscle health affects treatment outcomes. You may qualify if you have intermediate or advanced liver cancer or earlier stage that hasn't responded to prior treatments.
This study tests whether extra geriatric support before and after CAR-T cell therapy helps people 60 and older recover faster. It is for patients with B-cell non-Hodgkin lymphoma or multiple myeloma who are scheduled for an FDA-approved CAR-T treatment.
This study looks at how tired patients feel during the first month after receiving CAR-T cell therapy, a special type of treatment for lymphoma that uses your own immune cells. The goal is to better understand the side effects of this therapy, especially fatigue, so that doctors can improve how they care for patients.
This trial tests a new type of CAR T-cell therapy that targets two proteins (CD20 and CD19) on your cancer cells. It is for people with certain types of lymphoma that have not responded to or have come back after at least two prior treatments.
Hear when a new Non-hodgkin Lymphoma,B Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.